Previous article
Newborn With Enlarged Bowel
Sep 2025
Next article
Diagnosis of Acute Pancreatitis Using a Clinical Risk Score
STEPS
New Drug Reviews

Donanemab (Kisunla) for the Slowing of Alzheimer Disease

Megan Adelman, PharmD, BCPS, BCGP
Megan L. Hull, PharmD, BCACP

American Family Physician. 2025;112(3):320-321.

Author disclosure: No relevant financial relationships.

MEGAN ADELMAN, PharmD, BCPS, BCGP, Cleveland Clinic Akron General Center for Family Medicine, Akron, Ohio

MEGAN L. HULL, PharmD, BCACP, OhioHealth Grant Family Medicine, Columbus

Address correspondence to Megan Adelman, PharmD, BCPS, BCGP, at Adelmam2@ccf.org.

Author disclosure: No relevant financial relationships.

  1. 1.DailyMed. Drug label information. Kisunla–donanemab-azbt injection, solution. Accessed March 30, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190352d4-ef62-4679-b4fa-e846e2766afa
  2. 2.DailyMed. Drug label information. Leqembi–lecanemab injection, solution. Accessed March 30, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
  3. 3.Sims JR, Zimmer JA, Evans CD, et al.; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527.
  4. 4.Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.
  5. 5.Wessels AM, Belger M, Johnston JA, et al. Demonstration of clinical meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): association between change in iADRS scores and patient and caregiver health outcomes. J Alzheimers Dis. 2022;88(2):577-588.
  6. 6.Wessels AM, Rentz DM, Case M, et al. Integrated Alzheimer's Disease Rating Scale: clinically meaningful change estimates. Alzheimers Dement (N Y). 2022;8(1):e12312.
  7. 7.Ebell MH, Barry HC, Baduni K, et al. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50-62.
  8. 8.Tonegawa-Kuji R, Hou Y, Hu B, et al. Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: a systematic review and meta-analysis. PLoS Med. 2025;22(3):e1004568.
  9. 9.Lilly Support Services. Kisunla (donanemab-azbt) injection for intravenous use 350mg/20mL. Accessed April 3, 2025. https://kisunla.lilly.com/support-resources

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Previous article
Newborn With Enlarged Bowel
Sep 2025
Next article
Diagnosis of Acute Pancreatitis Using a Clinical Risk Score

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.